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1. Introduction 
Periodontal disease is a chronic bacterial infection of the periodontium affecting the tissues 
surrounding and supporting the teeth. Periodontal disease progression is associated with 
subgingival bacterial colonization and biofilm formation principal to chronic inflammation of 
soft tissues, degradation of collagen fibers supporting the tooth to the gingiva and alveolar 
bone, as well as resorption of the alveolar bone itself. Since the fundamental role of 
microorganisms in its etiology was systematically demonstrated some forty years ago, 
research efforts have long focused on identifying the pathogenic microorganisms and their 
virulence factors (Socransky and Haffajee, 1994). The search for these putative microorganisms 
was driven, in part, by knowledge indicating that colonization of the oral cavity and presence 
of dental biofilm is normally associated with health, similarly to the colonization of the colon. 
To treat periodontal diseases as an infectious disease, numerous therapeutic strategies aimed 
at eradication of periodontal pathogens have been studied over the years, including local and 
systemic delivery of antimicrobial and antibiotic agents. This review will cover an update on 
chemotherapeutic agents used adjunctively to treat and manage periodontal diseases.  
In the current paradigm of periodontal disease, specific periodontal pathogens are necessary 
for disease initiation; however, the extent and severity of tissue destruction are largely 
dependent on the nature of the host-microbial interactions. These interactions are dynamic, 
since both the microbial composition of the dental biofilm and the competency of host 
immune responses can vary, in the same individual, over time. This concept was developed 
in parallel to the advances on the understanding of the immune response, and research on 
periodontal disease has been emphasizing mechanisms of host-microbial interactions to 
understand the disease process, as well as for the development of novel therapeutic 
strategies. For the past two decades, the host response to the bacterial challenge originating 
from the dental biofilm has been considered to play a major role on both initiation of the 
disease and on the tissue destruction associated with its progress (Kirkwood, et al., 2007). 
The importance of host-microbial interactions is reinforced by epidemiological data 
indicating different susceptibilities to periodontal disease among individuals, in spite of the 
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long-term presence of oral biofilm (Baelum and Fejerskov, 1986, Baelum, et al., 1988, Loe, et 
al., 1986). Other studies demonstrating increased susceptibility and greater severity of 
periodontal disease in individuals with impaired immune response due to systemic 
conditions also indicate the significance of the host response to the bacterial challenge (Feller 
and Lemmer, 2008, Mealey, 1998). Both past and future directions of host-modulatory 
agents will be addressed here to provide the dental practitioner with a broader prospective 
of chemotherapeutic agents used to manage periodontal diseases.  
2. Antibiotics 
Contemporary periodontal therapies aim at mechanical removal of bacterial deposits to 
maintain a healthy sulcus or produce an environment suitable for new attachment. The 
inability of mechanical treatment to produce a desirable root surface in all cases coupled 
with the nature and complexity of the subgingival biofilm has fueled the search for 
adjunctive treatment regimens that increase the likelihood to successfully manage 
periodontal diseases. 
While more than 700 bacterial species may be present in the gingival sulcus, it is clear that 
only a subset of bacterial species are consistently found to be associated with diseased sites. 
These findings make the prospect of targeted antibiotic therapy an attractive goal. The 
literature on antimicrobial periodontal therapy has been thoroughly reviewed (Ellen and 
McCulloch, 1996, Goodson, 1994, van Winkelhoff, et al., 1996).  
2.1 Systemic antibiotics 
Adjunctive systemic antibiotic therapies have indicated beneficial effects for patients with 
periodontal diseases., The optimal timing of antimicrobial drug administration is still a 
subject of discussion, as the literature is controversial whether it should be administered 
during the initial non-surgical phase (Loesche, et al., 1992), or during a subsequent surgical 
phase (Herrera, et al., 2008). Although not directly confirmed yet by a clinical trial, it seems 
preferable, from a general health point of view, to let patients benefit early from the positive 
systemic effects of successful periodontal therapy. Table 1 provides an overview of some 
orally active systemic antibiotics commonly used in clinical periodontics.  
Caution should be noted that none of these antibiotics is to be used as a monotherapy to treat 
periodontal diseases. Systemic antibiotics reach the periodontal tissues by transudation from 
the serum then cross the crevicular and junctional epithelia to enter the gingival sulcus. The 
concentration of the antibiotic in this site may be inadequate for the desired antimicrobial 
effect without mechanical disruption of the plaque biofilm. In addition to any effect produced 
in the sulcus, a systemically administered antibiotic will produce antimicrobial effects in other 
areas of the oral cavity. This additional effect will reduce bacterial counts on the tongue and 
other mucosal surfaces, thus potentially aiding to delay re-colonization of subgingival sites. 
Research however, indicates that antibiotics are detectable in the sulcus and the range of their 
concentrations in the gingival crevicular fluid is known to be in therapeutic range treatment 
efficacy. Table 2 provides information to facilitate the clinician’s decision to the most 
reasonable choice of antibiotic, dose and duration of administration. 
Many studies have been completed and published describing the effect of systemic 
antibiotic therapy on periodontal disease. Several different treatment regimens have been 
employed successfully to manage periodontal diseases (Slots and Ting, 2002). Considering a 
number of studies, it can be stated generally that systemic antibiotic therapy has little effect 
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on supragingival plaque accumulation with a possible exception in one study where 
doxycycline significantly decreased plaque accumulation at a twelve-week evaluation 
compared to placebo (Ng and Bissada, 1998). 
 
Antibiotic 
Class 
Agent Effect 
Target 
Organisms 
Limitation 
Penicillin Amoxicillin Bacteriocidal 
Gram + and 
Gram - 
Penicillinase sensitive 
Patient 
hypersensitivity 
 Augmentin Bacteriocidal 
Narrower 
spectrum 
than 
Amoxicillin 
More expensive than 
Amoxicillin 
Tetracycline Tetracycline Bacteriostatic 
Gram + > 
Gram - 
Bacterial resistance 
 Minocycline Bacteriostatic 
Gram + > 
Gram - 
 
 Doxycycline Bacteriostatic 
Gram + > 
Gram - 
 
Quinolone Ciprofloxacin Bacteriocidal Gram - rods Nausea, GI discomfort 
Macrolide Azithromycin 
Bacteriostatic 
OR 
Bacteriocidal 
depending on 
concentration 
  
Lincomycin Clindamycin Bacteriocidal 
Anaerobic 
bacteria 
 
Nitroimidazole Metronidazole
Bacteriocidal 
to Gram - 
Gram -; esp. 
P. gingivalis 
and  
P. intermedia 
Not good choice for A. 
Actinomycetemcomitans 
infections 
Table 1. Systemic antibiotic choices. 
 
Single Agent Regimen Dosage/Duration 
Amoxicillin 500 mg Three times per day X 8 days 
Azithromycin 500 mg Once daily X 4-7 days 
Ciprofloxacin 500 mg Twice daily X 8 days 
Clindamycin 300 mg Three times daily X 10 days 
Doxycycline or Minocycline 100-200 mg Once daily X 21 days 
Metronidazole 500 mg Three times daily X 8 days 
   
Combination Therapy   
Metronidazole + Amoxicillin 250 mg of each Three times daily X 8 days 
Metronidazole + Ciprofloxacin 500 mg of each Twice daily X 8 days 
Table 2. Systemic antibiotic dosing regimens. 
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Except for the combination of metronidazole with amoxicillin, systemic antibiotic treatment 
produces no clinically significant effects on periodontal pocket depth reduction compared 
with controls (Winkel, et al., 2001) ((Cionca, et al., 2009). A seven-day regimen of systemic 
metronidazole significantly reduced the percentage of sites with bleeding compared to 
controls (Watts, et al., 1986). Others have reported a 12-month reduction in bleeding after 
treatment with a metronidazole-amoxicillin combination compared to a placebo treatment 
(Lopez, et al., 2000). With respect to clinical attachment levels, systemic metronidazole and 
combinations of metronidazole with other antibiotics has shown improvement in several 
studies. Several investigators found significant improvement of attachment levels at sites 
initially 4-6 mm in depth with a seven-day treatment with metronidazole (Elter, et al., 1997, 
Loesche, et al., 1992, Loesche, et al., 1984). Winkel et al. showed that the combination of 
metronidazole and amoxicillin for 7 to 14 days produced a significant increase in the 
percentage of sites showing improved attachment levels compared to control sites (Winkel, 
et al., 2001). A combination of metronidazole and clindamycin for three weeks also 
produced improved attachment levels. (Gomi, et al., 2007, Sigusch, et al., 2001). 
Some data to date supports a clinical benefit from the use of azithromycin as a systemic 
approach in combination with mechanical routines. In one limited study, seventeen subjects 
receiving azithromycin (500 mg), three days before full-mouth scaling and root planing 
produced greater clinical improvement than in seventeen subjects treated with full-mouth 
scaling and root planing alone (Gomi, et al., 2007). Dastoor et al. studied thirty patients who 
reported smoking more than one pack per day and presented with periodontitis. A 
comparison was made between the response to treatment with periodontal surgery and 500 
mg Azithromycin per day for three days and treatment with periodontal surgery only. The 
addition of Azithromycin did not enhance improvements seen in both groups for 
attachment gain, depth reduction and reduction of bleeding on probing. However, the 
adjunctive use of Azithromycin was associated with a lower gingival index at two weeks 
and what the authors saw as more rapid wound healing. The addition of Azithromycin also 
produced reductions of red-complex bacteria that were maintained to three months 
(Dastoor, et al., 2007). 
It is important to remember that the systemic antibiotic therapy is not intended as a 
monotherapy but is always best as an adjunctive therapy combined with traditional 
mechanical therapy and patient plaque control.  
2.2 Local antibiotic therapy 
After considering the risk to benefit ratio of systemic antibiotic administration as an adjunct 
treatment of periodontal diseases, interest in antibiotic therapy applied locally was 
developed. Historically, the first such local antibiotic therapy for periodontal disease was 
the Actisite(no longer commercially available) fiber system. Actisite was supplied as 
hollow, nonabsorbable fibers filled with tetracycline (12.7 mg/9 inch fiber). The fiber was 
inserted into the pocket, wrapped repeatedly circumferentially around the tooth keeping the 
fiber in the pocket. Often a periodontal dressing was placed to aid maintaining the fiber in 
the pocket. The fiber was retained for ten days until operator removal. During this ten-day 
period drug concentrations of more than 1300 µg/ml of tetracycline were achieved and 
maintained. When the fiber was removed the soft tissue was often distended allowing 
temporary improved access and visibility of the root surfaces for any additional root planing 
or calculus removal. Following removal of the fiber the soft tissues generally showed 
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shrinkage and pocket reduction and reduction of the inflammatory response were 
commonly seen. The Actisite system, while very effective, was tedious to use and required 
the second visit for removal of the fiber. These issues fueled the development of an 
absorbable system (Table 3). 
 
Antimicrobial 
Agent 
Delivery 
Form 
Drawback 
GCF 
Concentration
Time to 
Absorption 
Brand Name 
Tetracycline 
12.7 mg per 9 
inches of fiber 
Hollow fibers
2nd procedure 
for fiber 
removal 
>1300 ug/ml 
for 10 days 
Not 
absorbable 
Actisite  
No longer 
commercially 
available 
10% 
Doxycycline 
Fluid; multi-
site 
depending on 
volume of 
site; in 
syringe 
Often pulls 
out when 
removing 
syringe 
250 ug/ml still 
noted at 7 
days 
21 days Atridox 
25% 
Metronidazole 
Gel 
Fluid;  
multi-site 
depending on 
volume of site; 
in syringe 
May require 
multiple 
applications 
for desirable 
results 
More than 120 
mg/ml of 
sulcus fluid in 
the first few 
hours 
Concentration 
decreases 
rapidly after 
the first few 
hours (Knoll-
Kohler, 1999) 
Elyzol 
2% 
Minocycline 
Spheres 
Solid; in unit 
doses applied 
with syringe 
Unit doses 
may not be 
sufficient for 
every site 
volume 
Therapeutic 
drug levels for 
14 days 
14 days Arestin 
Table 3. Local antibiotic delivery systems. 
The first resorbable local antibiotic system was Atridox(Atrix Laboratories). In this system, 
longer half-lived doxycycline replaced tetracycline supplied at a concentration of 42.5 mg 
per unit of material. Atridox improved the local antibiotic routines by allowing placement 
of the material to the depth of most pockets and in a manner that allowed it to conform to 
the shape of the pocket unlike the solid fibers of Actisite. Depending on the size of the 
pocket, more than one site could be treated with a single unit of Atridox. 
Further development of absorbable local antibiotic systems led to Arestin (OraPharma) 
that uses minocycline in a microsphere configuration, each sphere measuring 20-60 microns 
in diameter. The antibiotic maintains therapeutic drug levels and remains in the pocket for 
14 days. This configuration of the material allows placement to the depths of most pockets 
and while the material cannot conform to the shape of the pocket as well as the Atridox 
gel it is still better than the solid Actisite fibers. 
Another material, not available in the United States, is Elyzol(Colgate), a metronidazole 
gel system. This material is supplied as 25% metronidazole in a glyceryl mono-oleate and 
sesame oil base. The concentration of Metronidazole in this system is 250 mg/g of material 
that is applied as a gel using a syringe method.   
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Overall efficacy of local antibiotic therapies has been evaluated using meta-analysis of fifty 
articles, each reporting studies of at least six months follow-up (Bonito, et al., 2005). The 
meta-analysis considered studies of the addition of local adjuncts and found such additions 
provide generally favorable but minimal differences. The clinical effects of these various 
systems have been reported in several publications. Table 4 summarizes several studies of 
various local adjunctive materials. The overall treatment effect is somewhat variable and 
while found to be statistically significant has led many to be suspect of the general clinical 
benefit.  
 
Agent Subjects
Depth 
Change 
with S/RP 
Only 
Depth 
Change 
with S/RP + 
Agent 
Sites With At Least 2 mm 
Attachment Gain with S/RP + 
Agent 
Tetracycline Fibers 
(Goodson, et al., 1991)
107 0.67 
1.02 
(fiber only)
Not reported 
Doxycycline gel 
(Garrett, et al., 1999) 
411 1.08 
1.30 
(drug only)
38% (drug only) 
Doxycycline gel 
(Wennstrom, et al., 
2001) 
105 1.3 1.5 52% 
Doxycycline gel 
(Machion, et al., 2006)
48 1.5 - 2.19 1.63-2.29 34.4% vs. 18.1% S/RP only 
Minocycline spheres 
(Williams, et al., 2001)
728 1.08 1.32 42% 
Minocycline spheres 
(Goodson, et al., 2007)
127 1.01 1.38 
Not reported; reports attachment 
gain of 1.16 with agent, 0.8 S/RP 
only 
Metronidazole gel 
(Ainamo, et al., 1992) 
206 1.3 
1.5 
(drug only)
Not reported 
Azithromycin gel  
(Pradeep, et al., 2008) 
80 2.13 2.53 
Not reported; reports greater 
gain at all time points with agent 
Table 4. Local Antibiotic System Studies. 
3. Antiseptics 
The use of chemical agents with anti-plaque or anti-gingivitis action as adjuncts to oral 
hygiene seems to be of limited value, since mouthrinses do not appreciably penetrate into 
the gingival crevice, but they are of specific benefit when used as adjuncts to control 
gingival inflammation, especially in acute situations and during periods of interrupted 
hygiene (Ciancio, 1989). The challenge with chemical plaque control is to develop an  
active anti-plaque agent that does not disturb the natural flora of the oral cavity. The 
American Dental Association (ADA) Seal of Acceptance is seen as a standard for oral health 
care products. The ADA Seal Program ensures that professional and consumer  
dental products meet rigorous ADA criteria for safety and effectiveness. Guidelines  
have been established for the control of gingivitis and supragingival plaque 
www.intechopen.com
Present and Future Non-Surgical Therapeutic  
Strategies for the Management of Periodontal Diseases 
 
303 
(http://www.ada.org/ada/seal/index.asp). These guidelines describe the clinical, 
biological, and laboratory studies necessary to evaluate safety and effectiveness and are 
subject to revision at any time. Importantly, they do not describe criteria for evaluating the 
management of periodontitis or other periodontal diseases. All claims of efficacy, including 
all health benefit claims, (e.g. gingivitis reduction), and all claims which imply a health 
benefit (e.g. plaque reduction) must be documented. There will be two Seal statements to be 
used with an Accepted product, depending on whether or not the product’s mechanism of 
action is related to plaque reduction.  
Oral antiseptics have evolved from short-lived effects (soon after rinsing) as with the first 
generation antimicrobials (Table 5) to the second generation, which have the antimicrobial 
effect that lasts for a time period after the mouthrinse has been expectorated (Table 6).  
 
Anti-
microbial 
Commercial 
Name 
ADA Seal 
of 
Acceptance
Active 
ingredients 
Alcohol 
content
Mechanism of 
Action 
Efficacy published  
by the manufacturer 
Phenolic 
Compounds 
Listerine  
(Johnson & 
Johnson) 
Yes 
Essential 
oils: 
Thymol 
(0.06%) 
Eucalyptol 
(0.09%) 
Methyl 
salicylate 
(0.06%) 
Menthol 
(0.04%) 
26.9% 
Appears to be 
related to 
alteration of the 
bacterial cell 
wall 
52% plaque 
reduction 
36% gingivitis 
reduction 
(www.listerine.com) 
Sanguinarine 
Viadent 
(Colgate) 
No 
0.03% 
Sanguinarin
e extract 
5.5% 
Alteration of 
bacterial cell 
surfaces so that 
aggregation and 
attachment is 
reduced 
28% plaque 
reduction 
24% gingivitis 
reduction 
(www.colgateprofes
sional.com/products
/Viadent-Advanced-
Care-Oral-
Rinse/details) 
Quaternary 
Ammonium 
Compounds 
Cepacol and 
Scope 
(Procter & 
Gamble) 
No 
Cepacol: 
0.05% CPC 
 
Scope: 
0.045% CPC 
+ 0.005% 
domiphen 
bromide 
Cepacol 
14% 
 
Scope 
18.9% 
Related to 
increased 
bacterial cell wall 
permeability, 
which favors 
lysis, decreased 
cell metabolism 
and a decreased 
ability for bacteria 
to attach to tooth 
surfaces. 
15.8% plaque 
reduction 
15.4% gingivitis 
reduction  
(www.cepacol.com/
products/mouthwas
h.asp) and 
(www.pg.com/prod
uct_card/prod_card
_main_scope.html) 
Table 5. First generation antimicrobials. 
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On the downside, it is also recognized that oral hygiene products may have the potential for 
producing harm in the mouth, some of which are more serious and long lasting than others. 
These types of harm range from production of a cosmetic nuisance, such as staining 
occurring as a result of the use of cationic antiseptics like chlorhexidine and cetylpyridinium 
chloride, to more permanent damage to the dental hard tissues through possible erosive and 
abrasive effects of low-pH mouthrinses and toothpastes respectively. Of serious concern is 
controversially the ability to produce carcinogenic changes to the oral mucosa through the 
use of alcoholic mouthrinses. Recently, the potential harm of oral hygiene products to oral 
and systemic health was fully reviewed with reference to present-day evidence (Addy, 
2008). 
 
Antimicrobial 
Cetylpyridinium 
chloride 
Chlorhexidine 
Commercial 
Name 
Crest Pro-Health 
(Procter & Gamble)
Peridex (3M Espe)
Periogard (Colgate)
ADA Seal of 
Acceptance 
No Yes 
 
Active 
ingredients 
0.07% CPC 
0.12% Chlorhexidine gluconate 
(solutions.3m.com/wps/portal/3M/en_US/pr
eventive-care/home/products/home-care-
therapies/peridex/) and 
(www.colgateprofessional.com/products/Colg
ate-Periogard-Rinse-Rx-only/details) 
 
Mechanism of 
Action 
Bactericidal agent 
interacts with the bacterial 
membrane. The cellular 
pressure disrupts the cell 
membrane and effectively 
kills the bacteria.
Positively charged chlorhexidine molecule 
binds to negatively charged microbial cell wall, 
altering osmotic equilibrium, causing potassium 
and phosphorous leakage, precipitation of 
cytoplasmic contents and consequent cell death. 
 
Efficacy 
published by 
the 
manufacturer 
Similar to Listerine 
(www.dentalcare.com/so
ap/products/index.htm)
Certain aerobic and anaerobic bacteria 
reduction from 54 - 97% through six months use 
(solutions.3m.com/wps/portal/3M/en_US/pr
eventive-care/home/products/home-care-
therapies/peridex/) 
-  29% gingivitis reduction 
-  54% plaque reduction 
(www.colgateprofessional.com/products/Colg
ate-Periogard-Rinse-Rx-only/details) 
Table 6. Second generation antimicrobials. 
3.1 Phenolic compounds 
Among the first generation antimicrobials, the phenolic compounds, such as Listerine and 
its clones, are the only ones that have the ADA Seal of Acceptance to prevent and reduce 
supragingival plaque accumulation and gingivitis. Short-term studies have shown plaque 
and gingivitis reduction averaging 35% (Fornell, et al., 1975) and long-term studies have 
shown plaque reduction between 13.8 and 56.3% and gingivitis reduction between 14 and 
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35.9% (DePaola, et al., 1989, Gordon, et al., 1985). Possible adverse effects reported in the 
literature include a burning sensation, bitter taste and possible staining of teeth. 
3.2 Chlorhexidine 
Chlorhexidine gluconate (0.12%), such as Peridex and Periogard, is sold in the United 
States by prescription only. It was the first antimicrobial shown to inhibit plaque formation 
and the development of chronic gingivitis (Loe and Schiott, 1970). Chlorhexidine is effective 
against gram-positive and negative bacteria and yeast. It has very low toxicity, since it is 
poorly absorbed from the GI tract and 90% is excreted in the feces. Chlorhexidine 0.12% is 
indicated for short-term (less than 2 months), intermittent short-term (alternating on and off 
every 1 to 2 months) and long-term (greater than 3 months to indefinitely) use (Table 7). Of 
all the products included here, chlorhexidine appears to be the most effective agent for 
reduction of both plaque and gingivitis with short-term reductions averaging 60% (Flotra, et 
al., 1972). Long-term reductions in plaque averaged between 45-61% and in gingivitis, 27-
67% (Ciancio, 1989). Adverse effects reported may include staining of teeth, reversible 
desquamation, poor taste and alteration of taste and an increase in supragingival calculus 
(Flotra, et al., 1972, Overholser, et al., 1990). 
 
Short-term 
indication 
(less than 2 
months) 
Intermittent short-term 
indications 
(alternating on and off 
every 1 to 2 months) 
Long-term indications 
(greater then 3 months to indefinitely) 
Gingivitis Gingivitis 
Patients with reduced resistance to 
bacterial plaque: AIDS, leukemia, kidney 
disease, bone marrow transplants, 
agranulocytosis, thrombocytopenia 
Following 
periodontal and 
oral surgery 
Periodontal maintenance 
Physically handicapped patients: 
rheumatoid arthritis, scleroderma, 
disturbance of muscles and/or motor 
capacity and coordination 
During initial 
periodontal 
therapy 
Physically and /or mentally 
handicapped 
Patients treated with: cytotoxic drugs, 
immunosuppressive drugs, and 
radiation therapy. 
Treatment of 
candidiasis 
Extensive prosthetic 
reconstruction 
 
Table 7. Chlorhexidine 0.12% Indications. 
3.3 Other antimicrobial mouthrinses  
Several other agents have been evaluated for their effect on bacterial plaque and gingivitis, 
but results are inferior to those of chlorhexidine and phenolic compounds (see Table 8). 
Pires et al. (Pires, et al., 2007) have concluded that a mouthwash containing a combination of 
Triclosan/Gatrez and sodium bicarbonate has an in-vitro antimicrobial activity superior to 
that of a placebo, but still inferior to that of chlorhexidine. 
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Anti-
microbial 
Commercial 
Name 
ADA  
Seal of 
Acceptance
Active 
ingredients 
Mechanism of Action Efficacy 
Oxygenating 
agents 
Peroxyl 
(Colgate) 
No 
Hydrogen 
Peroxyde 
Anti-inflammatory 
properties reduce bleeding 
on probing, a major sign of 
inflammation; bacterial load 
is not necessarily reduced; 
bubbling action cleans and 
alleviates discomfort to 
promote healing.
Long-term studies do 
not support 
effectiveness. 
Short-term studies 
offer contradictory 
findings. 
Chlorine 
Dioxide 
RetarDEX 
(Periproducts)
 
Oxyfresh 
No 
1% chlorine 
dioxide 
Stable, free radical and an 
oxidant with algicidal, 
bactericidal, cysticidal, 
fungicidal, sporicidal, and 
viricidal properties. 
Minimal plaque 
reduction, but has 
shown decreases 
involatile sulfur 
compounds and 
halitosis. 
Zinc 
Chloride 
Breath Rx No 
-Zinc 
chloride 
-Phenolic oils 
(Thymol and 
Eucalyptus 
oil) 
Zinc has an affinity to 
sulfur and odorizes 
sulphydryl groups with 
zinc ions forming stable 
mercaptides with the 
substrate, the precursors, 
and/or the volatile sulfur 
compounds directly.
BreathRx is a 
scientific bad breath 
treatment specially 
designed to help 
treat both the causes 
of bad breath and the 
symptoms. 
Triclosan 
Not available 
in the US 
N/A Triclosan 
A low toxicity, non-ionic 
phenolic derivative with a 
wide spectrum of 
antimicrobial and anti-
inflammatory activities 
(Kim, et al., 2005).
In vitro studies show 
antimicrobial activity 
superior to that of a 
placebo, but inferior to 
that of chlorhexidine 
(Pires, et al., 2007) 
Table 8. Other antimicrobial mouthrinses. 
 
Antiseptics 
compared 
Methodology Results References 
Listerine 
Viadent 
Peridex 
Placebo 
31 volunteers with healthy gingiva 
ceased all oral hygiene procedures 
but rinsing with the designated 
mouthrinse for 21 days 
Peridex was superior in its 
ability to maintain optimal 
gingival health during the entire 
time of mouthrinse use. 
Siegrist et al. 
(Siegrist, et al., 
1986) 
Listerine 
Peridex 
Placebo 
Double blind, controlled clinical 
trial. After a baseline complete 
dental prophylaxis,124 healthy 
adults used the mouthrinse as a 
supplement to regular oral hygiene 
for 6 months.  
Both Listerine and Peridex 
significantly inhibited 
development of plaque by 36.1% 
and 50.3%, respectively, and the 
development of gingivitis by 
35.9% and 3.0.5% respectively, 
compared to placebo. 
Overholser et al. 
(Overholser, et 
al., 1990) 
Chlorhexidine 
0.12% 
Hydrogen 
Peroxide 1% 
Placebo 
32 subjects ceased oral hygiene 
procedures, but rinsed, twice a day, 
with the designated mouthrinse for 
21 days. 
The chlorhexidine group showed 
95% reduction in gingivitis 
incidence, 100% reduction in BOP, 
and 80% reduction in plaque 
scores compared to placebo. 
Gusberti et al. 
(Gusberti, et al., 
1988) 
Table 9. Comparison studies. 
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4. Anti-inflammatory strategies  
It is well established that periodontal disease is an infectious disease and that the host 
immune and inflammatory response to the microbial challenge mediates tissue destruction 
(Offenbacher, 1996). Considering that the primary etiology of the disease are bacteria in the 
plaque and their products, mechanical and chemical approaches to reduce the presence of 
periodontopathogens in the plaque have been largely used in the treatment of periodontal 
patients over the years (Greenwell, 2001). Most recently, the better understanding of the 
participation of host immune-inflammatory mediators in the disease progression has 
increased the investigation of the use of modulating agents as an adjunctive therapy to the 
periodontal treatment. Inhibition or blockade of proteolytic enzymes, pro-inflammatory 
mediators and of osteoclast activity has been the focus of these agents which has lead to 
encouraging results in pre-clinical and clinical studies (Reddy, et al., 2003). More 
specifically, three types of host-modulatory agents have been investigated for the 
management of periodontitis including anti-proteinases (MMP inhibitors), anti-
inflammatory agents, and anti-resorptive agents. 
4.1 MMP Inhibitors 
One important group of proteolytic enzymes present in the periodontal tissues is formed by 
the matrix metalloproteinases (MMPs), which include collagenases, gelatinases and 
metalloelastases. MMPs are produced by many periodontal tissues and are responsible for 
remodeling the extracellular matrix (Birkedal-Hansen, 1993). In 1985, tetracyclines were 
found to have anti-collagenolytic activity and proposed as a host modulating agent for 
periodontal treatment (Golub, et al., 1985). Initial studies demonstrated that doxycycline 
was the most potent tetracycline in inhibition of collagenolytic activities (Burns, et al., 1989). 
This property of doxycycline provided the pharmacological rationale for the use of a low or 
subantimicrobial dose of doxycycline (SDD) that was shown to be efficient in inhibiting 
mammalian collagenase activity without developing antibiotic resistance (Golub, et al., 
1990). 
Several clinical studies have been conducted assessing the benefits of the SDD as an 
adjunctive therapy to scaling and root planing (SRP) in the treatment of the periodontal 
disease. Reddy et al. recently presented a meta-analysis (Reddy, et al., 2003) of 6 selected 
clinical studies comparing long-term systemic SDD (20mg bid doxycycline) to placebo 
control in periodontal patients. A statistically significant adjunctive benefit on clinical 
attachment levels (CAL) and probing depth was found when SDD was used in combination 
with SRP, in both 4 to 6mm and ≥ 7mm pocket depth categories. Bleeding on probing (BOP) 
was not assessed in the meta-analysis but, in general, SDD did not improve this parameter 
when compared to placebo. No significant adverse effects were reported in any of the 
studies.  
4.2 Non-steroid anti-inflammatory drugs  
The non-steroidal anti-inflammatory drugs (NSAIDs) represent the next major 
pharmacological class of agents that has been well studied as inhibitors of the host response 
in periodontal disease. These agents are well known for the ability to prevent prostanoid 
formation. In this process, arachidonic acid liberated from membrane phospholipids of cells 
after tissue damage or stimulus is metabolically transformed via cyclooxygenase or 
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lipoxygenase pathways in compounds with potent biological activities (Offenbacher, 1996). 
The cyclooxygenase enzymes are recognized to have two isoforms: cyclooxygenase 1 
(COX1) which is a constitutive enzyme present in most of cells and cyclooxygenase 2 
(COX2) which is inducible and is present in cells involved in inflammatory processes 
(DeWitt, et al., 1993). The cyclooxygenase pathway produces prostaglandins, prostacyclin 
and thromboxane, called prostanoids. Some prostanoids have proinflammatory properties 
and have been associated with destructive process in inflammatory diseases. In periodontal 
diseases, Prostaglandin E2 (PGE2) has been extensively correlated to inflammation and bone 
resorption (Offenbacher, 1996). Its levels in gingival tissues and in the gingival crevicular 
fluid (GCF) have been shown to be significantly elevated in periodontally diseased patients 
compared to healthy patients (Dewhirst, et al., 1983, Offenbacher, et al., 1981). 
Selective NSAIDs are capable of inhibiting COX-2 without affecting constitutive isoform 
COX-1. Some studies have indicated that COX-2 inhibitors retain bone sparing effects 
(Bezerra, et al., 2000, Holzhausen, et al., 2002, Holzhausen, et al., 2005, Shimizu, et al., 1998) 
without inducing adverse effects associated with COX-1 suppression, such as gastro-
duodenal problems and renal toxicity (Hawkey, 1993, Lindsley and Warady, 1990). Several 
adjunctive periodontal clinical trials have been conducted with NSAIDs. In a systematic 
review (Reddy, et al., 2003), ten clinical studies in which therapeutic outcomes of NSAIDs 
were expressed in clinical attachment level (CAL) or alveolar crestal height as measured by 
subtraction radiography were selected. In these studies a variety of different NSAIDs were 
systemically or locally administered, including flurbiprofen, meclofenamate, ibuprofen, 
ketorolac, naproxen and aspirin. Although the heterogeneity of data did not permit a meta-
analysis, limited quantitative analysis tended to show a significant benefit related to alveolar 
bone maintenance when NSAIDs were combined with conventional therapy. Notably, none 
of these studies found significantly less attachment loss after NSAIDs adjunctive therapy 
when compared to SRP alone.  
4.3 Anti-bone resorptive therapeutics 
Alveolar bone destruction is the hallmark feature of periodontal disease. The use of bone-
sparing drugs that inhibit alveolar bone resorption is another field in host-modulation 
therapy. Bisphosphonates are a class of agents that binds to hydoxyapatite in bone matrix to 
prevent matrix dissolution by interfering with osteoclast function through a variety of direct 
and indirect mechanisms (Rogers, et al., 2000). The principal therapeutic purpose of 
bisphosphonates is in the prevention and treatment of osteoporosis and also in treatment of 
Paget’s disease and metastatic bone disease (Fleisch, 1997). In periodontics, their use was 
proposed initially for diagnostic and therapeutic use. As therapeutic agents, 
bisphosphonates were shown to reduce alveolar bone loss and increase mineral density but 
not to improve clinical conditions in animal periodontitis models (Brunsvold, et al., 1992, 
Reddy, et al., 1995). Five studies that assessed the effect of bisphosphonates as an adjunctive 
agent to SRP in human periodontal treatment were found to date (El-Shinnawi and El-
Tantawy, 2003, Jeffcoat, et al., 2007, Lane, et al., 2005, Rocha, et al., 2004, Rocha, et al., 2001). 
Alendronate was the bisphosphonate used in four studies during a period of 6 months. One 
study used risedronate during 12 months (El-Shinnawi and El-Tantawy, 2003). All the 
studies presented significant clinical improvement when compared to placebo, including: 
probing depth reduction, clinical attachement gain, bleeding on probing reduction, alveolar 
bone gain and increase in bone mineral density. These results encourage the use of 
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bisphosphonates as an adjunctive agent to periodontal therapy. Additional studies need to 
be implemented to confirm the benefits of these drugs. 
However, there can be significant dental related adverse effects associated with the use of 
bisphosphonates therapeutics. High-dose, long-term use of bisphosphonates has been 
reported to be associated with osteonecrosis of the jaw (ONJ) (Marx, 2003, Ruggiero, et al., 
2004). Data from multiple sources indicates that patients with prior dental problems may 
have a higher risk of ONJ. However, as more data is being reported, it still remains 
controversial that bisphosphonates indeed are causative for ONJ. Since bisphosphonates are 
potent osteoclast inhibitors, their long-term use may suppress bone turnover and 
compromise healing of even physiologic micro-injuries within bone (Odvina, et al., 2005). 
Despite the encouraging therapeutic results, further long-term studies are warranted to 
determine the relative risk-benefit ratio of bisphosphonate therapy.  
5. Future host modulatory approaches 
A variety of treatment strategies have been developed to target the host response to LPS-
mediated tissue destruction. MMP inhibitors such as low dose formulations of doxycycline 
have been used in combination with scaling and root planing (Caton, et al., 2001) or surgical 
therapy (Gapski, et al., 2004). In addition, high-risk patient populations such as diabetics or 
patients with recurrent periodontal disease have benefited from systemic MMP 
administration (Chang, et al., 1996, Golub, et al., 2001, Novak, et al., 2002). Encouraging 
results have been shown using soluble antagonists of TNF and IL-1 delivered locally to 
periodontal tissues in nonhuman primates (Assuma, et al., 1998, Graves, et al., 1998).  
5.1 Novel host modulators 
Host response modulation is key therapeutic target used to control periodontal 
inflammation leading to tissue and bone destruction. Bone loss as a consequence of 
bacterial-induced inflammation due to subgingival plaque in the periodontal pocket is 
controlled by the expression of cytokines that direct the biological process of osteoclast 
differentiation. Several inflammatory cytokines, including interleukin (IL)-1, IL-6 and other 
cytokines enhance the expression of receptor activator of nuclear factor kappa-B ligand 
(RANKL) which induced osteoclast formation and leads to bone resorption. RANK is the 
receptor located on osteoclast precursor cells that respond to RANKL to initiate formation of 
mature osteoclasts. To balance the effects of RANKL, osteoprotegerin (OPG) acts as a decoy 
receptor to bind RANKL and inhibits osteoclast development. In periodontal disease, the 
roles of RANKL, RANK, and OPG in the alveolar bone resorption have been extensively 
investigated. Based on pre-clinical animal studies and on preliminary human clinical 
studies, the OPG/RANKL/RANK axis is a new target for the treatment of destructive 
periodontal disease and other bone resorption related diseases (Cochran, 2008). However, 
further studies are necessary to determine the most efficacious therapeutic approach based 
upon molecular interactions in the periodontal environment. 
All immune cells within periodontal tissues generate innate immune cytokines require 
intracellular signaling to transduce extracellular cues into biochemical information required 
for inflammatory cytokine gene expression. Cytokines and bacterial components activate 
many signal transduction pathways. With this concept in mind, new strategies for 
preventing cell activation via targeting signal transduction pathways could abolish both cell 
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activation by cytokines or other stimuli and production of proinflammatory cytokines. 
Signal transduction pathways closely involved in inflammation include the mitogen-
activated protein kinase (MAPK) pathway, phosphatidylinositol-3 protein (PI3-kinase) 
pathway, janus kinase-signal transducer and activator of transcription (Jak-STAT), and 
nuclear factor kappa B (NF-kB). Thus, small molecule inhibitor compounds have emerged as 
the new therapeutic strategies that are being explored are aimed at inhibiting signal 
transduction pathways involved in inflammation. Pharmacological inhibitors of NF-kB and 
p38 mitogen activating protein (MAP) kinase pathways are actively being developed to 
manage inflammatory bone diseases (Adams, et al., 2001, Kumar, et al., 2001). p38 inhibitors 
have already shown promise in preclinical models of periodontal diseases (Kirkwood, et al., 
2007, Rogers, et al., 2007). Using this novel strategy, inflammatory mediators including 
proinflammatory cytokines (IL-1, TNF, IL-6), MMPs and others would be inhibited at the 
level of cell signaling pathways required for transcription factor activation necessary for 
inflammatory gene expression or mRNA stability. These therapies may provide the next 
wave of adjuvant chemotherapeutics that may be used to manage chronic periodontitis.  
6. Future directions  
Most therapeutics has relied on systemic delivery. Thus, it may be difficult to potentially use 
systemic therapeutics for periodontal disease due to the long-term chronic nature of the 
periodontal inflammation and destruction. The future may be the adjunctive use of locally 
delivered therapeutics, and the need for new targets of therapeutics for periodontal disease. 
Also, the need for new in situ delivery systems with the ability to locally deliver 
therapeutics to the periodontal lesion bypassing systemic issues of toxicity.  
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